Rice Hall James & Associates, LLC Kiniksa Pharmaceuticals, Ltd. Transaction History

Rice Hall James & Associates, LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 23, 2024	SELL	$17.63 - $21.74 $303,782 - $374,601	-17,231 Reduced 2.71%	618,798 $12.2 Million
Q4 2023 Feb 08, 2024	SELL	$14.37 - $19.07 $206,022 - $273,406	-14,337 Reduced 2.2%	636,029 $11.2 Million
Q3 2023 Nov 02, 2023	SELL	$13.62 - $20.2 $132,903 - $197,111	-9,758 Reduced 1.48%	650,366 $11.3 Million
Q2 2023 Jul 24, 2023	BUY	$10.44 - $16.48 $46,645 - $73,632	4,468 Added 0.68%	660,124 $9.29 Million
Q1 2023 May 11, 2023	SELL	$10.7 - $15.79 $444,114 - $655,379	-41,506 Reduced 5.95%	655,656 $7.05 Million
Q4 2022 Jan 27, 2023	SELL	$11.42 - $17.05 $602,644 - $899,745	-52,771 Reduced 7.04%	697,162 $0
Q3 2022 Nov 01, 2022	SELL	$9.76 - $13.41 $631,862 - $868,163	-64,740 Reduced 7.95%	749,933 $9.63 Million
Q2 2022 Aug 08, 2022	BUY	$7.6 - $11.41 $20,907 - $31,388	2,751 Added 0.34%	814,673 $7.89 Million
Q1 2022 May 05, 2022	BUY	$9.3 - $12.37 $921,769 - $1.23 Million	99,115 Added 13.9%	811,922 $8.07 Million
Q4 2021 Feb 14, 2022	SELL	$10.39 - $15.15 $255,251 - $372,190	-24,567 Reduced 3.33%	712,807 $8.39 Million
Q3 2021 Nov 09, 2021	BUY	$11.39 - $16.23 $34,261 - $48,819	3,008 Added 0.41%	737,374 $8.4 Million
Q2 2021 Jul 29, 2021	BUY	$13.22 - $19.09 $899,131 - $1.3 Million	68,013 Added 10.21%	734,366 $10.2 Million
Q1 2021 May 14, 2021	BUY	$16.68 - $23.97 $1.11 Million - $1.6 Million	66,836 Added 11.15%	666,353 $12.3 Million
Q4 2020 Feb 16, 2021	BUY	$14.8 - $21.15 $8.87 Million - $12.7 Million	599,517 New	599,517 $10.6 Million

1.95M

Ticker KNSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,470,400
Market Cap $751M
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...

Get notified when there are updates to the investment portfolio of Rice Hall James & Associates, LLC, based on Form 13F filings with the SEC.

Stay updated on Rice Hall James & Associates, LLC with notifications on news.